James P. Boylan - 15 Jun 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Director
Issuer ticker: ZBIO
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 18:01:20 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jeffrey Held, Attorney-in-Fact

Key filing fact

James P. Boylan filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 17 Jun 2026.

Key facts

This page summarizes James P. Boylan's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 18:01.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001953094 Primary reporting owner

Boylan James P

Relationship: Director
Address: C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM
Signature: By: /s/ Jeffrey Held, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,500
Change %
Price: $0.000000^*
Shares after: 18,500
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,500
Exercise price: $18.71
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.

Footnote F2

The reporting person holds the stock option, and the shares underlying the option, for the benefit of Enavate Sciences, L.P. Accordingly, the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any.